Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Dabigatran Shows Non-Inferiority to Warfarin: BI
December 21, 2009
- Wholesalers’Primary Profit on Sales -2.04% in FY2008: Mr Matsutani
December 21, 2009
- Sumitomo Chemical, Kracie to Codevelop Scabies Treatment
December 21, 2009
- Diversifying Business Not the Cure for “Patent Cliff”: Datamonitor
December 21, 2009
- BioComber Licenses Cell-Free Protein Synthesis Technology to Chugai
December 21, 2009
- Merck Serono Aims at 10% Market Share for hGH Saizen
December 21, 2009
- 60% of ED Treatments Sold Online Are Counterfeits
December 21, 2009
- TMX-67 to Drive Teijin's Business: Mr Ohyagi
December 21, 2009
- Benefits of an Attitude of Gratitude
December 21, 2009
- Takara Bio Obtains Patent on Expansion Culture of Lymphocytes
December 21, 2009
- DPP-4/GLP-1 Drugs Need Further Assessment in Actual Medical Practice: Prof. Niki
December 21, 2009
- CMIC Acquires DS Propharma's Shizuoka Plant
December 21, 2009
- Taxotere to Become New Treatment Option for Prostate Cancer: Prof. Akaza
December 21, 2009
- GSK Files for Rotavirus Vaccine Rotarix
December 14, 2009
- DSP to Spin Off Animal Health, Food & Speciality Products
December 14, 2009
- FDA Advisory Committee Supports Safety, Efficacy of Prevnar 13
December 14, 2009
- EFPIA Japan Appoints Masuhiro Kato Chairman
December 14, 2009
- More Than 60% of Patients Dissatisfied with Existing Oral Hypoglycemic Agents
December 14, 2009
- No New Safety Measures Required for Lantus: PMDA
December 14, 2009
- GRU's WG Demands Reductions in METI's Budgets for Drug Discovery Research
December 14, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…